Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SCYNEXIS Inc SCYX

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.


NDAQ:SCYX - Post by User

<< Previous
Bullboard Posts
Next >>
Post by JonathanJSmithon Apr 27, 2021 10:18am
168 Views
Post# 33073738

Time for options w/upcoming PDUFA date?

Time for options w/upcoming PDUFA date?Which June call should I buy?

For fun I ran the numbers assuming a $12,000 investment w/commissions ignored, and here's what I got*:

--------------------------------------------------
1) Strike $7.50, cost $1.20 per contract = 100 contracts (or 10K shares)
2) Strike $10.00, cost $0.70/c = 171 calls (17.1K shares)
3) Strike $17.50, cost $0.15/c = 800 calls (80K shares)

Product gets approved and stock price jumps to the following:

$15, Result:

1) Gain = ($15 - $8.70) x 10K = $63K
2) Gain = ($15 - $10.70) x 17.1K = $73.5K
3) Gain = ($12,000)

$20, Result:

1) Gain = ($20 - $8.70) x 10K = $113K
2) Gain = ($20 - $10.70) x 17.1K = $159K
3) Gain = ($20 - $17.65) x 80K = $188K

$25, Result:

1) Gain = ($25 - $8.70) x 10K = $163K
2) Gain = ($25 - $10.70) x 17.1K = $244.5K
3) Gain = ($25 - $17.65) x 80K = $588K


* based on most recent sales (Yahoo!)

--------------------------------------------------

I guess it all boils down to how high one believes the stock will jump by the expiry date.
Of course, there's always the $7.50 straddle in case one's worried about a CRL! ;)

Cheers and good luck!

JJ
<< Previous
Bullboard Posts
Next >>